COPD患者最大用力吸气流量纵向变化与临床结局的关系
该纵向研究评估了956例COPD患者2004至2020年间最大用力吸气流量(FIFmax)的轨迹变化,按FIFmax升高或降低分组,比较急性加重年发生率与FEV1年下降率。倾向评分匹配后,FIFmax升高组重度急性加重率更低、FEV1下降更慢,尤其在特定吸入治疗(如干粉吸入器)患者中更明显。
要点
- FIFmax纵向升高与COPD重度急性加重率降低相关。
- FIFmax升高组FEV1年下降速度更慢。
- 使用干粉吸入器等特定吸入治疗者中关联更突出。
核心结论
- COPD患者FIFmax纵向变化与临床结局相关,FIFmax升高者重度急性加重率更低且肺功能下降更慢。
研究设计与样本
- 纵向研究,纳入2004至2020年7年间956例COPD患者,按FIFmax轨迹分为升高组与降低组。
- 采用倾向评分匹配后比较两组急性加重年发生率与FEV1年下降率,并按治疗状态(吸入治疗及吸入装置使用)进行亚组分析。
主要发现
- 956例COPD患者中56.5%属于FIFmax升高组。
- 倾向评分匹配后,FIFmax升高组重度急性加重率为每年0.16次,低于降低组的每年0.25次(P = .017)。
- FIFmax升高组FEV1年下降为0 mL/y(四分位距-51至71),降低组为-43 mL/y(四分位距-119至6),P < .001。
- 上述关联在使用干粉吸入器等特定吸入治疗的患者中尤为突出。
临床怎么用
- 在COPD管理中可关注FIFmax的纵向变化,将其作为评估急性加重与肺功能下降风险的参考指标。
- 对使用干粉吸入器等特定吸入装置的患者,优化吸气流量可能有助于改善临床结局。
局限性
- 研究为观察性设计,存在潜在混杂因素,结论需进一步研究确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: COPD primarily impairs expiratory flow due to progressive airflow obstruction and reduced lung elasticity. Increasing evidence underlines the importance of inspiratory flow as a biomarker for selecting inhaler devices and providing ancillary aerodynamic information. RESEARCH QUESTION: Do the longitudinal changes in maximum forced inspiratory flow (FIFmax) influence acute exacerbations and lung function decline in patients with COPD? STUDY DESIGN AND METHODS: This longitudinal study evaluated FIFmax in patients with COPD over a 7-year period from 2004 to 2020. Eligible patients were categorized into two groups based on FIFmax trajectory: the increased FIFmax group and the decreased FIFmax group. The study assessed the annual rate of acute exacerbations and the annual decline rate of FEV1. Subgroup analyses were conducted based on treatment status, with a focus on inhaled therapy and inhaler device usage. RESULTS: Among the eligible 956 patients with COPD, 56.5% belonged to the increased FIFmax group. After propensity score matching, the increased FIFmax group experienced lower rates of severe exacerbations (0.16 per year vs 0.25 per year, P = .017) and a slower decline in FEV1 (0 [interquartile range, -51 to 71] mL/y vs -43 [interquartile range, -119 to 6] mL/y; P < .001) compared with the decreased FIFmax group. These associations were particularly prominent in patients using specific inhaler therapies such as dry powder inhalers. INTERPRETATION: This study showed that the longitudinal changes in FIFmax are associated with clinical outcomes in patients with COPD. Patients with increased FIFmax experienced a lower rate of severe exacerbations and a slower decline in lung function. These findings suggest the potential benefits of optimizing inspiratory flow in COPD management, although further studies are needed to confirm these observations due to potential confounding factors.
引用
- Kim DH, Jeon ET, Lee HJ, et al. Longitudinal Changes in Maximal Forced Inspiratory Flow and Clinical Outcomes in Patients With COPD. Chest. 2024. PMID: 39151822. doi:10.1016/j.chest.2024.07.162
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。